New Appointments at London Genetics to Drive Strate...( LONDON September 18 /- London Gen...)

LONDON, September 18 /PRNewswire/ -- London Genetics Limited, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of excellence in genetics research, announces today several prestigious appointments to its Board and management team. The new appointments, which include Dr Barrie Ward as Chairman, will drive the next phase of the company's growth as the importance of pharmacogenetics in drug development increases. They bring important commercial, clinical and academic expertise.

In addition to Dr Ward, London Genetics has appointed Dominique Kleyn as CEO and Dr Mark Caulfield as Clinical Director. Having held senior positions at Glaxo R&D and various biotechnology companies in the US and UK, Dr Ward brings significant industrial and commercial expertise. Ms Kleyn joins from a series of leadership roles at Imperial College London, where she headed up bioscience Business Development, Technology Transfer and New Venture teams. Prior to this she worked in the biotech sector where she was extensively involved in the exploitation and licensing of intellectual property and development of new businesses. Clinical Director Dr Mark Caulfield is an expert in the genetics of cardiovascular disease, particularly hypertension. He is Director of the William Harvey Research Institute at Bart's and the London School of Medicine and Dentistry at Queen Mary, University of London.

Pharmacogenetics is the study of how our genetic make-up affects the way in which we metabolise and respond to drugs. As a result, it is expected to play a key role in the future of drug development and healthcare delivery as the industry faces increasing pressure to replenish its pipeline and improve drug safety. By combining its access to genetic expertise with strategic advice on the application of pharmacogenetics in drug development, London Genetics can help companies meet this need f
'/>"/>